Literature DB >> 35777848

Characterization of Mycobacterium tuberculosis-Specific Th22 Cells and the Effect of Tuberculosis Disease and HIV Coinfection.

Mohau S Makatsa1, F Millicent A Omondi1, Rubina Bunjun1, Robert J Wilkinson2,3,4,5, Catherine Riou1,2,3, Wendy A Burgers6,2,3.   

Abstract

The development of a highly effective tuberculosis (TB) vaccine is likely dependent on our understanding of what constitutes a protective immune response to TB. Accumulating evidence suggests that CD4+ T cells producing IL-22, a distinct subset termed "Th22" cells, may contribute to protective immunity to TB. Thus, we characterized Mycobacterium tuberculosis-specific Th22 (and Th1 and Th17) cells in 72 people with latent TB infection or TB disease, with and without HIV-1 infection. We investigated the functional properties (IFN-γ, IL-22, and IL-17 production), memory differentiation (CD45RA, CD27, and CCR7), and activation profile (HLA-DR) of M. tuberculosis-specific CD4+ T cells. In HIV-uninfected individuals with latent TB infection, we detected abundant circulating IFN-γ-producing CD4+ T cells (median, 0.93%) and IL-22-producing CD4+ T cells (median, 0.46%) in response to M. tuberculosis The frequency of IL-17-producing CD4+ T cells was much lower, at a median of 0.06%. Consistent with previous studies, IL-22 was produced by a distinct subset of CD4+ T cells and not coexpressed with IL-17. M. tuberculosis-specific IL-22 responses were markedly reduced (median, 0.08%) in individuals with TB disease and HIV coinfection compared with IFN-γ responses. M. tuberculosis-specific Th22 cells exhibited a distinct memory and activation phenotype compared with Th1 and Th17 cells. Furthermore, M. tuberculosis-specific IL-22 was produced by conventional CD4+ T cells that required TCR engagement. In conclusion, we confirm that Th22 cells are a component of the human immune response to TB. Depletion of M. tuberculosis-specific Th22 cells during HIV coinfection may contribute to increased risk of TB disease.
Copyright © 2022 The Authors.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35777848      PMCID: PMC9339498          DOI: 10.4049/jimmunol.2200140

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  57 in total

1.  Anti-tuberculosis treatment enhances the production of IL-22 through reducing the frequencies of regulatory B cell.

Authors:  Mingxia Zhang; Gucheng Zeng; Qianting Yang; Jieyun Zhang; Xiuyun Zhu; Qi Chen; Pichaimuthu Suthakaran; Ying Zhang; Qunyi Deng; Haiying Liu; Boping Zhou; Xinchun Chen
Journal:  Tuberculosis (Edinb)       Date:  2013-12-20       Impact factor: 3.131

2.  Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.

Authors:  Mark Hatherill; Thomas J Scriba; Sara Suliman; Hennie Geldenhuys; John L Johnson; Jane E Hughes; Erica Smit; Melissa Murphy; Asma Toefy; Lesedi Lerumo; Christiaan Hopley; Bernadette Pienaar; Phalkun Chheng; Elisa Nemes; Daniel F Hoft; Willem A Hanekom; W Henry Boom
Journal:  J Immunol       Date:  2016-07-13       Impact factor: 5.422

3.  Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes.

Authors:  Aida Sivro; Alexandra Schuetz; Daniel Sheward; Vineet Joag; Sergey Yegorov; Lenine J Liebenberg; Nonhlanhla Yende-Zuma; Andrew Stalker; Ruth S Mwatelah; Philippe Selhorst; Nigel Garrett; Natasha Samsunder; Anisha Balgobin; Fatima Nawaz; Claudia Cicala; James Arthos; Anthony S Fauci; Aggrey Omu Anzala; Joshua Kimani; Bernard S Bagaya; Noah Kiwanuka; Carolyn Williamson; Rupert Kaul; Jo-Ann S Passmore; Nittaya Phanuphak; Jintanat Ananworanich; Aftab Ansari; Quarraisha Abdool Karim; Salim S Abdool Karim; Lyle R McKinnon
Journal:  Sci Transl Med       Date:  2018-01-24       Impact factor: 17.956

Review 4.  Variation in protection by BCG: implications of and for heterologous immunity.

Authors:  P E Fine
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

5.  Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses.

Authors:  Liyou Qiu; Dan Huang; Cystal Y Chen; Richard Wang; Ling Shen; Yun Shen; Robert Hunt; James Estep; Barton F Haynes; William R Jacobs; Norman Letvin; George Du; Zheng W Chen
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

6.  IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion.

Authors:  Rohan Dhiman; Mohanalaxmi Indramohan; Peter F Barnes; Ramesh C Nayak; Padmaja Paidipally; L Vijaya Mohan Rao; Ramakrishna Vankayalapati
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

7.  Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis.

Authors:  Hans-Willi Mittrücker; Ulrich Steinhoff; Anne Köhler; Marion Krause; Doris Lazar; Peggy Mex; Delia Miekley; Stefan H E Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-18       Impact factor: 11.205

8.  Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands.

Authors:  Yelina Alvarez; Michael Tuen; Guomiao Shen; Fatima Nawaz; James Arthos; Martin J Wolff; Michael A Poles; Catarina E Hioe
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

9.  Th22 Cells Are a Major Contributor to the Mycobacterial CD4+ T Cell Response and Are Depleted During HIV Infection.

Authors:  Rubina Bunjun; Fidilia M A Omondi; Mohau S Makatsa; Roanne Keeton; Jerome M Wendoh; Tracey L Müller; Caryn S L Prentice; Robert J Wilkinson; Catherine Riou; Wendy A Burgers
Journal:  J Immunol       Date:  2021-08-13       Impact factor: 5.422

Review 10.  Role of Group 1 CD1-Restricted T Cells in Infectious Disease.

Authors:  Sarah Siddiqui; Lavanya Visvabharathy; Chyung-Ru Wang
Journal:  Front Immunol       Date:  2015-06-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.